A comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN) reveals key trends in cancer incidence and mortality worldwide. Lung cancer remained the most common cancer and leading cause of cancer death globally. Thyroid cancer cases increased significantly in 2022, while stomach and esophageal cancer cases and deaths declined. The geographic distribution of cancer incidence and mortality across six continents in 2022 was largely similar to that of 2020. Higher Human Development Index (HDI) levels correlated with higher cancer incidence and mortality rates. China's age-standardized incidence rate (ASIR) ranked 64th and its age-standardized mortality rate (ASMR) ranked 68th, aligning with global averages. Lung cancer continued to impose the greatest burden of incidence and mortality. Stomach, breast, and esophageal cancers showed declines in both case counts and ASIR. Noteworthy reductions in both ASMR and absolute mortality numbers were observed in liver, stomach, and esophageal cancers. The global MIR decreased from 0.516 in 2020 to 0.488 in 2022. MIR trends indicated an upward trajectory with decreasing HDI levels in both 2022 and 2020. While Canada, Germany, India, Italy, Japan, and the United Kingdom demonstrated increasing MIRs, China exhibited the most significant decrease, followed by Russia and the United States. The study highlights the ongoing trends in cancer incidence and mortality, with cancer burdens varying significantly across countries with different socioeconomic statuses. Decreases in stomach, liver, and esophageal cancer cases and deaths signify progress in cancer control efforts. The decrease in the global MIRs highlights potential improvements in cancer management. The global cancer burden is influenced by factors such as population aging, lifestyle changes, and socioeconomic development. The study underscores the importance of targeted interventions to address disparities in cancer outcomes and healthcare access. The findings emphasize the need for continued efforts in research, innovation, and collaboration to achieve equitable cancer outcomes worldwide.A comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN) reveals key trends in cancer incidence and mortality worldwide. Lung cancer remained the most common cancer and leading cause of cancer death globally. Thyroid cancer cases increased significantly in 2022, while stomach and esophageal cancer cases and deaths declined. The geographic distribution of cancer incidence and mortality across six continents in 2022 was largely similar to that of 2020. Higher Human Development Index (HDI) levels correlated with higher cancer incidence and mortality rates. China's age-standardized incidence rate (ASIR) ranked 64th and its age-standardized mortality rate (ASMR) ranked 68th, aligning with global averages. Lung cancer continued to impose the greatest burden of incidence and mortality. Stomach, breast, and esophageal cancers showed declines in both case counts and ASIR. Noteworthy reductions in both ASMR and absolute mortality numbers were observed in liver, stomach, and esophageal cancers. The global MIR decreased from 0.516 in 2020 to 0.488 in 2022. MIR trends indicated an upward trajectory with decreasing HDI levels in both 2022 and 2020. While Canada, Germany, India, Italy, Japan, and the United Kingdom demonstrated increasing MIRs, China exhibited the most significant decrease, followed by Russia and the United States. The study highlights the ongoing trends in cancer incidence and mortality, with cancer burdens varying significantly across countries with different socioeconomic statuses. Decreases in stomach, liver, and esophageal cancer cases and deaths signify progress in cancer control efforts. The decrease in the global MIRs highlights potential improvements in cancer management. The global cancer burden is influenced by factors such as population aging, lifestyle changes, and socioeconomic development. The study underscores the importance of targeted interventions to address disparities in cancer outcomes and healthcare access. The findings emphasize the need for continued efforts in research, innovation, and collaboration to achieve equitable cancer outcomes worldwide.